Check how courts have cited this case. Use our free citator for the most current treatment.
No. 10386175
United States Court of Appeals for the Ninth Circuit
United States v. Pangang Group Company, Ltd.
No. 10386175 · Decided April 28, 2025
No. 10386175·Ninth Circuit · 2025·
FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
April 28, 2025
Citation
No. 10386175
Disposition
See opinion text.
Full Opinion
FOR PUBLICATION
UNITED STATES COURT OF APPEALS
FOR THE NINTH CIRCUIT
UNITED STATES OF AMERICA, No. 22-10058
Plaintiff-Appellee,
D.C. Nos.
v. 4:11-cr-00573-
JSW-7
PANGANG GROUP COMPANY, 4:11-cr-00573-
LTD.; PANGANG GROUP STEEL JSW-8
VANADIUM & TITANIUM 4:11-cr-00573-
COMPANY, LTD.; PANGANG JSW-9
GROUP TITANIUM INDUSTRY 4:11-cr-00573-
COMPANY, LTD.; PANGANG JSW-10
GROUP INTERNATIONAL
ECONOMIC & TRADING OPINION
COMPANY,
Defendants-Appellants.
Appeal from the United States District Court
for the Northern District of California
Jeffrey S. White, District Judge, Presiding
Argued and Submitted January 26, 2024
Pasadena, California
Filed April 28, 2025
2 USA V. PANGANG GROUP COMPANY, LTD.
Before: Kim McLane Wardlaw, Daniel P. Collins, and
Daniel A. Bress, Circuit Judges.
Opinion by Judge Collins
SUMMARY *
Criminal Law / Foreign Sovereign Immunity
The panel affirmed the district court’s denial of a motion
to dismiss an indictment charging four affiliated companies
(“the Pangang Companies”) with economic espionage in
connection with their alleged efforts to steal from E.I. du
Pont de Nemours & Company trade secrets relating to the
production of titanium dioxide.
The Pangang Companies maintained that they enjoy
foreign sovereign immunity from criminal prosecution in the
United States because they are ultimately owned and
controlled by the government of the People’s Republic of
China (“PRC”). In a prior appeal, this court held that the
Pangang Companies failed in their effort to invoke the
immunity conferred by the Foreign Sovereign Immunities
Act (“FSIA”) because they had not made the requisite prima
facie showing that they fall within the FSIA’s domain of
covered entities.
After the district court on remand again rejected the
Pangang Companies’ remaining claims of foreign sovereign
immunity, including their claims based on federal common
*
This summary constitutes no part of the opinion of the court. It has
been prepared by court staff for the convenience of the reader.
USA V. PANGANG GROUP COMPANY, LTD. 3
law, the Pangang Companies again appealed. While this
appeal was pending, the Supreme Court held in Turkiye Halk
Bankasi A.S. v. United States, 598 U.S. 264 (2023), that the
common law, not the FSIA, governs whether foreign states
and their instrumentalities are entitled to foreign sovereign
immunity from criminal prosecution in U.S. courts.
Under federal common law, an entity must satisfy, at
minimum, two conditions to enjoy foreign sovereign
immunity from suit. First, it must be the kind of entity that
is eligible for any immunity at all—that is, it must fall within
the domain of foreign sovereign immunity. Second, its
immunity must extend to the conduct at issue in the suit—
that is, the entity’s conduct must fall within the scope of the
immunity conferred on such entities. The panel held that the
Pangang Companies did not make a prima facie showing that
they exercise functions comparable to those of an agency of
the PRC, and they therefore are not the kinds of entities
eligible for foreign sovereign immunity from criminal
prosecution. The panel did not reach the subsequent
question of scope.
The panel noted that principles of deference to the
political branches on matters touching on foreign relations
reinforce the conclusion that, under federal common law, the
Pangang Companies are not entitled to immunity.
COUNSEL
Matthew M. Yelovich (argued), Chief, Appellate Section,
Criminal Division; Colin C. Sampson, Merry J. Chan, and
Ross D. Mazer, Assistant United States Attorneys; Ismail J.
Ramsey, United States Attorney; Office of the United States
4 USA V. PANGANG GROUP COMPANY, LTD.
Attorney, United States Department of Justice, San
Francisco, California; for Plaintiff-Appellee.
Robert P. Feldman (argued) and Joseph E. Reed, Quinn
Emanuel Urquhart & Sullivan LLP, Redwood Shores,
California; John M. Potter, Quinn Emanuel Urquhart &
Sullivan LLP, San Francisco, California; William B. Adams,
Quinn Emanuel Urquhart & Sullivan LLP, New York, New
York; Alexander H. Loomis and Michael T. Packard, Quinn
Emanuel Urquhart & Sullivan LLP, Boston, Massachusetts;
for Defendants-Appellants.
OPINION
COLLINS, Circuit Judge:
Defendants-Appellants Pangang Group Company, Ltd.
(“PGC”); Pangang Group Steel Vanadium & Titanium
Company, Ltd. (“PGSVTC”); Pangang Group Titanium
Industry Company, Ltd. (“PGTIC”); and Pangang Group
International Economic & Trading Company (“PGIETC”)
(collectively, “the Pangang Companies”) are four affiliated
companies that have been indicted for economic espionage
in connection with their alleged efforts to steal trade secrets
from E.I. du Pont de Nemours & Company (“DuPont”)
relating to the production of titanium dioxide (“TiO2”).
They maintain that they enjoy foreign sovereign immunity
from criminal prosecution in the United States because they
are ultimately owned and controlled by the government of
the People’s Republic of China (“PRC”). In a prior appeal,
we held that the Pangang Companies failed in their effort to
invoke the immunity conferred by the Foreign Sovereign
USA V. PANGANG GROUP COMPANY, LTD. 5
Immunities Act (“FSIA”) because they had not made the
requisite prima facie showing that they fall within the
FSIA’s domain of covered entities. See United States v.
Pangang Grp. Co., 6 F.4th 946 (9th Cir. 2021) (“Pangang”).
After the district court on remand again rejected the
Pangang Companies’ remaining claims of foreign sovereign
immunity, including their claims based on federal common
law, the Pangang Companies have again appealed. While
this appeal was pending, the Supreme Court held in Turkiye
Halk Bankasi A.S. v. United States, 598 U.S. 264 (2023)
(“Halkbank II”) (affirming in part and vacating and
remanding in part United States v. Turkiye Halk Bankasi
A.S., 16 F.4th 336 (2d Cir. 2021) (“Halkbank I”)), that the
common law, not the FSIA, governs whether foreign states
and their instrumentalities are entitled to foreign sovereign
immunity from criminal prosecution in U.S. courts. Id. at
280. In light of Halkbank II, this appeal was rebriefed to
focus on the now-controlling issues concerning the extent to
which the Pangang Companies enjoy foreign sovereign
immunity under federal common law.
We hold that the Pangang Companies lack foreign
sovereign immunity from criminal prosecution and therefore
affirm the district court’s denial of the Pangang Companies’
motion to dismiss the indictment.
I
We begin by setting out the relevant factual and
procedural history. See also Pangang, 6 F.4th at 950–52.
On January 5, 2016, the Government filed the operative
Third Superseding Indictment, which charges the Pangang
Companies under the Economic Espionage Act (“EEA”)
with one count of conspiracy to commit economic espionage
under 18 U.S.C. § 1831(a)(5) and one count of attempted
6 USA V. PANGANG GROUP COMPANY, LTD.
economic espionage under 18 U.S.C. § 1831(a)(1)–(4). “We
presume the allegations of an indictment to be true for
purposes of reviewing a district court’s ruling on a motion to
dismiss.” United States v. Fiander, 547 F.3d 1036, 1041 n.3
(9th Cir. 2008) (citation omitted).
A
In the 1990s, the Chinese government “publicly
identified the development of chloride-route titanium
dioxide (TiO2) production technology as a scientific and
economic priority.” TiO2 is a “commercially valuable white
pigment” used in producing materials “ranging from paints
to plastics to paper.” While there was substantial demand
for TiO2 in China, the country was a net importer of the
compound “because PRC companies had not been able to
develop clean, efficient TiO2 production technology.”
“Chloride-route TiO2 production technology” was
sufficiently clean and efficient, but it “was closely held by
western companies, including [DuPont], which . . . was not
willing to sell or license its proprietary technology to PRC
companies.” DuPont was the largest TiO2 producer in the
world, and its proprietary chloride-route TiO2 production
technology included several trade secrets that the company
took care to protect.
“In order to develop chloride-route TiO2 production
capabilities . . . , companies owned and controlled by the
PRC government and employees of those companies,
including [the Pangang Companies] . . . , attempted to
illegally obtain technology that had been developed by
DuPont.” The Pangang Companies conspired with certain
individuals to steal DuPont’s TiO2 trade secrets and use them
USA V. PANGANG GROUP COMPANY, LTD. 7
in the design and operation of a chloride-route production
plant that the Pangang Companies were building in China. 1
In describing the defendants engaged in this conspiracy,
the indictment alleges that PGC, based in China’s Sichuan
Province, is a “state-owned enterprise controlled by” the
State-Owned Assets Supervision and Administration
Commission of the State Council (“SASAC”). The SASAC
is alleged to be “a special government agency of the PRC”
and “under the direct control of the State Council, the PRC’s
highest government authority.” The SASAC appoints the
executives of the entities it controls, and the government
provides strategic guidance to state-owned entities through
five-year plans that aim to provide overall coordination for
the national economy. The chairman and certain senior
managers of PGC are Chinese Communist Party officials.
The remaining Pangang Companies—PGSVTC,
PGTIC, and PGIETC—are alleged to be direct or indirect
subsidiaries of PGC and thus also controlled by the SASAC.
Specifically, PGC “controlled” and “shared senior
management with” its subsidiary PGSVTC, and PGTIC and
PGIETC are “subsidiaries” that “w[ere] owned and
controlled by” PGC and PGSVTC. In charging the Pangang
Companies with both conspiracy and attempt to commit
economic espionage, the indictment alleges that the Pangang
Companies stole and received DuPont’s trade secrets (and
attempted to do so) while “intending and knowing that the
offenses would benefit a foreign government, namely the
1
Several individuals were indicted as the Pangang Companies’ co-
conspirators, and most of them pleaded guilty or were convicted by a
jury. See In re Pangang Grp. Co., 901 F.3d 1046, 1049 n.1 (9th Cir.
2018).
8 USA V. PANGANG GROUP COMPANY, LTD.
PRC, and foreign instrumentalities, namely [the Pangang
Companies].”
B
On July 9, 2019, the Pangang Companies moved to
dismiss the indictment for failure to state an offense under
the EEA and for lack of jurisdiction under the FSIA. 2
Enacted in 1976, the FSIA “codifies a baseline principle of
immunity for foreign states and their instrumentalities” and
delineates exceptions to that immunity. Halkbank II, 598
U.S. at 272; see also 28 U.S.C. § 1604. The FSIA defines a
covered “foreign state” to “include[] a political subdivision
of a foreign state or an agency or instrumentality of a foreign
state as defined in subsection (b).” 28 U.S.C. § 1603(a).
Subsection (b) states, in relevant part, that an agency or
instrumentality of a foreign state is any entity “which is an
organ of a foreign state or political subdivision thereof, or a
majority of whose shares or other ownership interest is
owned by a foreign state or political subdivision thereof.”
Id. § 1603(b).
In arguing that the district court lacked jurisdiction, the
Pangang Companies asserted that the FSIA was the “sole
basis” for the jurisdiction of U.S. courts over a foreign state
and that “the FSIA grants immunity to foreign sovereigns
from criminal prosecution, absent an international
agreement stating otherwise.” The Pangang Companies
maintained that “[e]ven if the government were to contend
2
Before moving to dismiss the indictment in July 2019, the Pangang
Companies “repeatedly and successfully argued that the Government’s
efforts to serve summonses on the indictment were inadequate under
Federal Rule of Criminal Procedure 4,” until that rule was formally
amended and we affirmed the district court’s ruling that the
Government’s subsequent service attempt was valid. Pangang, 6 F.4th
at 951.
USA V. PANGANG GROUP COMPANY, LTD. 9
that federal common law applies, the result would be the
same” because “[u]nder common law, foreign states are
‘absolutely immune’ from the jurisdiction of United States
courts.” The Pangang Companies argued that this “exact
same immunity” applied to “instrumentalities” of a foreign
state under the FSIA and the common law. At the hearing
on the motion to dismiss, the Pangang Companies’ counsel
stated that, for purposes of that motion, “Defendants will
accept as true the [indictment’s] allegation that they are
foreign instrumentalities” within the meaning of the EEA.
The Pangang Companies argued that this allegation was
sufficient to establish that they were also foreign
instrumentalities within the meaning of the FSIA and
therefore entitled to immunity under that statute. See 28
U.S.C. §§ 1603, 1604. The Pangang Companies claimed
that the FSIA’s exceptions to foreign sovereign immunity
apply only in civil actions and that, even if they apply to
criminal prosecutions, the Government could not show any
such exception here.
On August 26, 2019, the district court denied the
Pangang Companies’ motion to dismiss the indictment,
holding that it had subject matter jurisdiction over the case
and that the Pangang Companies lacked immunity from suit
under the FSIA. See Pangang, 6 F.4th at 951–52.
Concluding that any differences between the definitions of
“foreign instrumentality” in the EEA and FSIA were
immaterial to the motion to dismiss, the court assumed,
without deciding, that the Pangang Companies also qualified
as foreign instrumentalities under the FSIA. The court
further stated “that it did not need to definitively resolve”
“whether the FSIA applies to criminal cases” because,
“[e]ven ‘assuming the FSIA applies in criminal cases,’ . . .
‘its exceptions apply as well.’” Id. at 951. Against this
10 USA V. PANGANG GROUP COMPANY, LTD.
backdrop, the court denied the Pangang Companies
immunity under the FSIA on two grounds. First, the court
held that the commercial activity exception to the FSIA
applied, see 28 U.S.C. § 1605(a)(2), because, as part of the
alleged conspiracy and attempt to commit economic
espionage, the Pangang Companies allegedly executed
commercial contracts with co-conspirators and held
meetings in the United States in connection with their TiO2
production projects, activities in which private actors could
engage. Second, the court held that the Pangang Companies’
multiyear participation in the case amounted to an implied
waiver of sovereign immunity under the FSIA, see 28 U.S.C.
§ 1605(a)(1). The court also rejected the Pangang
Companies’ alternative theory that the indictment failed to
state an offense under the EEA. The Pangang Companies
timely appealed.
On July 26, 2021, we affirmed the district court’s order
on different grounds, namely, that the Pangang Companies
had not shown they were foreign instrumentalities eligible
for immunity under the FSIA in the first place. See
Pangang, 6 F.4th at 960. Contrary to the Pangang
Companies’ argument and the district court’s assumption,
we held that, because the definition of foreign
instrumentality is “much broader” under the EEA than under
the FSIA, “the indictment’s allegation that the Pangang
Companies satisfy the former is insufficient to establish a
prima facie case that they meet the latter.” Id. We therefore
applied the FSIA’s definition of foreign instrumentality
directly, see 28 U.S.C. § 1603(b), and concluded that the
Pangang Companies failed to satisfy § 1603(b)(2). See
Pangang, 6 F.4th at 955–60. That provision of the FSIA
limits foreign instrumentalities to entities that are either
“organs” of or majority-owned by a foreign state. See 28
USA V. PANGANG GROUP COMPANY, LTD. 11
U.S.C. § 1603(b)(2). Because the Pangang Companies did
not contend that they were “organ[s] of a foreign state or
political subdivision thereof,” the “only question” was
whether “a majority of [each of the Pangang Companies’]
shares or other ownership interest is owned by a foreign state
or political subdivision thereof.” Pangang, 6 F.4th at 955
(alterations in original) (quoting 28 U.S.C. § 1603(b)(2)).
We held that the allegations in the indictment alone did not
establish that the Pangang Companies were directly
majority-owned by the PRC. Id. at 957–59; see also Dole
Food Co. v. Patrickson, 538 U.S. 468, 474 (2003) (holding
that “only direct ownership of a majority of shares by the
foreign state satisfies” the ownership condition of
§ 1603(b)(2) (emphasis added)). “Because the Pangang
Companies relied solely upon the indictment’s allegations,
and presented no evidence to support their motion to dismiss,
they necessarily failed to establish a prima facie case that
they were ‘foreign state[s]’ entitled to immunity under
§ 1604 of the FSIA.” Pangang, 6 F.4th at 960 (alteration in
original).
C
On November 30, 2021, the Pangang Companies again
moved to dismiss the indictment on foreign sovereign
immunity grounds. The Pangang Companies argued that,
despite our ruling, they were nonetheless foreign
instrumentalities entitled to immunity under the FSIA
inasmuch as (1) they had “submitted evidence in connection
with this [motion to dismiss] that fills the gap that the Ninth
Circuit identified as to the PRC’s majority-ownership of
Defendant [PGC],” and (2) “the Government’s own
submissions ma[de] a prima facie showing that Defendants
are organs of the PRC.” See 28 U.S.C. § 1603(b)(2).
Additionally, the Pangang Companies asserted that, if the
12 USA V. PANGANG GROUP COMPANY, LTD.
Government was correct that the common law of foreign
sovereign immunity and not the FSIA applied to criminal
proceedings, they had absolute immunity as common-law
foreign instrumentalities.
On February 25, 2022, the district court again denied the
Pangang Companies’ motion to dismiss. The court noted
that PGC, the only defendant to claim direct majority
ownership by the SASAC at the time of indictment, failed to
make a prima facie showing on this point because a
declaration from the Government’s expert attested that PGC
was only indirectly owned by the SASAC when indicted.
The court also rejected the Pangang Companies’ theory that
they were “organs” of the PRC entitled to immunity under
the FSIA. Noting that it would ordinarily treat the “organ”
argument as conceded because the Government did not
directly respond to it in opposing the motion to dismiss, the
court nonetheless stated that it “independently evaluated the
record” on this score “given the importance of the issues.”
In finding that the Pangang Companies failed to make a
prima facie showing of organ status, the district court relied
on caselaw holding that a foreign “organ” is an “entity [that]
engages in a public activity on behalf of the foreign
government.” EIE Guam Corp. v. Long Term Credit Bank
of Japan, 322 F.3d 635, 640 (9th Cir. 2003) (citation
omitted). “In making this determination, courts examine the
circumstances surrounding the entity’s creation, the purpose
of its activities, its independence from the government, the
level of government financial support, its employment
policies, and its obligations and privileges under state law.”
Id. (citation omitted). The district court noted that the
allegations in the operative indictment “focus on [the
Pangang Companies’] allegedly criminal conduct and do not
specifically address these factors.” The court found that the
USA V. PANGANG GROUP COMPANY, LTD. 13
Government expert’s declaration and other exhibits likewise
“do not address several of the relevant factors.” The court
therefore held that the record was insufficient to establish a
prima facie case of organ status for any of the Pangang
Companies.
In addition to rejecting the Pangang Companies’ FSIA-
based arguments on the ground that they were not foreign
instrumentalities under the FSIA, the district court supported
its denial of immunity on several alternative bases. Even
assuming arguendo that the Pangang Companies were
foreign instrumentalities under the FSIA, the court held that
the FSIA does not apply to criminal prosecutions. The court
also held that even if the FSIA applied to criminal
prosecutions, its exceptions to foreign sovereign immunity
would apply as well, and the court incorporated by reference
its previous conclusion that the charged acts fell within the
commercial activity and waiver exceptions. 3
Further, the district court rejected the Pangang
Companies’ argument that they “can be considered foreign
states under the common law.” The district court noted that
the Pangang Companies relied on the same factual record to
support both their common-law and FSIA arguments and
3
The district court addressed, in a footnote, our decision in Broidy
Capital Management, LLC v. State of Qatar, 982 F.3d 582 (9th Cir.
2020). The district court acknowledged Broidy’s holding that the
espionage at issue in that case did not fall within the commercial activity
exception because “a foreign government’s deployment of clandestine
agents to collect foreign intelligence on its behalf, without more, is the
sort of peculiarly sovereign conduct that all national governments
(including our own) assert the distinctive power to perform.” Id. at 595.
The district court concluded that “[t]he Ninth Circuit’s opinion in Broidy
supports this Court’s prior conclusion that Broidy was distinguishable
from the facts of this case because the defendant’s activities [in Broidy]
were ‘devoid of a commercial component.’”
14 USA V. PANGANG GROUP COMPANY, LTD.
that this record was “not sufficient to establish that they are
entitled to assert sovereign immunity under the common
law.” But even assuming that the Pangang Companies were
entitled to assert common-law immunity, the district court
concluded that any such immunity would not extend to the
instant prosecution. Citing the Second Circuit’s analysis of
common-law immunity in Halkbank I, the district court
stated that “‘customary international law’ recognizes the
restrictive theory of sovereign immunity, which would not
protect commercial activity.” The district court concluded
that, because it had determined that the Pangang Companies’
charged acts were commercial, the Pangang Companies
were not entitled to common-law foreign sovereign
immunity. On March 4, 2022, the Pangang Companies
appealed the district court’s decision.
II
While this appeal was pending, the Supreme Court
issued its decision in Halkbank II, which clarified several
important points relevant to this case. First, Halkbank II
confirmed that district courts have jurisdiction over criminal
prosecutions under 18 U.S.C. § 3231 even when the
defendants are “foreign states or their instrumentalities.”
See Halkbank II, 598 U.S. at 268–71. Second, Halkbank II
held that “the FSIA does not grant immunity to foreign states
or their instrumentalities in criminal proceedings.” Id. at
272. But the Court left open the possibility that foreign
states and their instrumentalities in criminal proceedings
may still have immunity under federal common law, and the
USA V. PANGANG GROUP COMPANY, LTD. 15
Court directed the court of appeals on remand to consider the
contours of any such immunity. See id. at 280–81. 4
In light of Halkbank II, the district court had subject
matter jurisdiction under 18 U.S.C. § 3231 notwithstanding
the Pangang Companies’ assertion of foreign sovereign
immunity. See id. at 270–71. We have jurisdiction under 28
U.S.C. § 1291 to review the interlocutory appeal of the
district court’s order denying immunity. See Pangang, 6
F.4th at 952–53.
Because Halkbank II disposes of the parties’ FSIA-based
arguments, the sole remaining issue on appeal is whether,
under federal common law, the Pangang Companies possess
foreign sovereign immunity from criminal prosecution. 5 We
review issues of sovereign immunity de novo. See Miller v.
Wright, 705 F.3d 919, 923 (9th Cir. 2013). Under the
common law, the “burden of proving sovereign immunity is
necessarily laid on the party who asserts it.” Bradford v.
Chase Nat’l Bank of New York, 24 F. Supp. 28, 36 (S.D.N.Y.
1938). A defendant need only make a “prima facie case”
4
“There is, of course, ‘no federal general common law.’” Texas Indus.,
Inc. v. Radcliff Materials, Inc., 451 U.S. 630, 640 (1981) (quoting Erie
R.R. Co. v. Tompkins, 304 U.S. 64, 78 (1938)). “Nevertheless, the Court
has recognized the need and authority in some limited areas to formulate
what has come to be known as ‘federal common law.’” Id. (citation
omitted).
5
The district court’s finding that the Pangang Companies impliedly
waived sovereign immunity by participating in these years-long
proceedings relied on the waiver exception within the FSIA. See 28
U.S.C. § 1605(a)(1). This waiver exception no longer applies to this case
because the Supreme Court held in Halkbank II that the FSIA does not
govern criminal prosecutions. See Halkbank II, 598 U.S. at 272–73.
Because the Government does not argue that the Pangang Companies
waived foreign sovereign immunity under the common law, we consider
the merits of the Pangang Companies’ immunity claim.
16 USA V. PANGANG GROUP COMPANY, LTD.
that it is entitled to sovereign immunity. See Pan Am.
Tankers Corp. v. Republic of Vietnam, 291 F. Supp. 49, 53
(S.D.N.Y. 1968). The Pangang Companies continue to rely
on the allegations in the operative indictment to establish a
prima facie case of immunity. See Pangang, 6 F.4th at 954.
III
Under federal common law, an entity must satisfy, at
minimum, two conditions to enjoy foreign sovereign
immunity from suit. First, it must be the kind of entity that
is eligible for any immunity at all—that is, it must fall within
the domain of foreign sovereign immunity. Second, its
immunity must extend to the conduct at issue in the suit—
that is, the entity’s conduct must fall within the scope of the
immunity conferred on such entities. We conclude that the
Pangang Companies do not fall within the domain of foreign
sovereign immunity. See infra Part IV. We therefore do not
reach the subsequent question of scope. 6
In assessing the domain of foreign sovereign immunity
from criminal prosecution under federal common law, we
are immediately confronted by the near-total lack of directly
applicable precedent. See Chimene Keitner, Prosecuting
6
On remand from the Supreme Court’s decision in Halkbank II, the
Second Circuit also held that the foreign state-owned defendant in that
case was not entitled to foreign sovereign immunity under the common
law, but it reached that conclusion on different grounds. See United
States v. Turkiye Halk Bankasi A.S., 120 F.4th 41 (2d Cir. 2024)
(“Halkbank III”). It held that the state-owned commercial bank indicted
there did not enjoy foreign sovereign immunity because the particular
conduct for which it was indicted was commercial and therefore did not
fall within the scope of such immunity. See id. at 58 (“Because the
indictment concerns Halkbank’s commercial activity, the Executive’s
position that Halkbank is not immune from prosecution based on that
activity is consistent with the scope of foreign sovereign immunity
recognized at common law.”).
USA V. PANGANG GROUP COMPANY, LTD. 17
Foreign States, 61 VA. J. INT’L L. 221, 240, 261 (2021)
(noting that “[t]he case law on foreign state immunity from
criminal proceedings remains relatively sparse” and that,
because prosecutions of foreign state-owned corporations by
the United States “post-dated the FSIA’s enactment,”
“Congress did not have criminal jurisdiction in mind” when
it enacted the FSIA). We agree with the Second Circuit that
this absence of directly applicable precedent should not be
taken as a point in favor of the view that foreign state-owned
entities must have been understood as categorically enjoying
foreign sovereign immunity from criminal prosecution
under the common law. See United States v. Turkiye Halk
Bankasi A.S., 120 F.4th 41, 55 n.11 (2d Cir. 2024)
(“Halkbank III”) (citing In re Grand Jury Subpoena, 912
F.3d 623, 630 (D.C. Cir. 2019) (characterizing such an
inference as “highly speculative” in light of other plausible
explanations for the absence of such caselaw)).
But despite the lack of directly controlling precedent, we
find relevant and helpful guidance in the available civil,
government-enforcement, and quasi-criminal precedents
addressing foreign sovereign immunity under the common
law. Because we perceive no basis to believe, and neither
side has given any reason to conclude, that the domain of
immunity from criminal liability would extend more broadly
than the domain of immunity from liability in these other
contexts, we draw upon precedents arising in the latter
contexts in considering the domain issue here. See Halkbank
III, 120 F.4th at 51 n.7 (“[T]he Supreme Court has indicated
that grand jury cases are relevant to the foreign sovereign
immunity analysis in criminal proceedings overall.”); id. at
54 (stating that courts have applied comparable common-
law immunity principles in both criminal and civil
proceedings). We examine cases from both state and federal
18 USA V. PANGANG GROUP COMPANY, LTD.
courts. See United States v. Ellis, 714 F.2d 953, 955 (9th
Cir. 1983) (“[F]ederal courts may look to other sources in
developing federal common law, including the law of the
states.”).
A
Traditionally, the common law conferred absolute
immunity on foreign sovereigns. See Verlinden B.V. v.
Central Bank of Nigeria, 461 U.S. 480, 486 (1983); see also
Federal Republic of Germany v. Philipp, 592 U.S. 169, 182
(2021). The domain of immunity under this traditional rule
included the persons of foreign sovereigns and ambassadors
and certain public property, such as ships. See, e.g., The
Schooner Exchange v. McFaddon, 11 U.S. 116, 137–38
(1812); The Navemar, 303 U.S. 68, 74 (1938); Republic of
Mexico v. Hoffman, 324 U.S. 30, 33–36 (1945).
As foreign state-owned entities started increasingly to
engage in ordinary commercial activities in the United
States, courts began to face the question whether these
entities likewise enjoyed foreign sovereign immunity. Cases
in the first half of the 20th century generally held that they
did not. As we shall explain, the early caselaw generally
concluded that foreign state-owned entities that engaged in
ordinary commercial activities did not fall within the domain
of foreign sovereign immunity, even if they were owned by
a foreign sovereign and even if their commercial activities
furthered the public interests of the foreign sovereign. Only
if a foreign state-owned entity performed fundamental
government functions could it fall within the domain of
immunity. Accord Halkbank III, 120 F.4th at 53 (“Given the
focus on government function, in certain cases involving
state-owned corporations, courts declined to extend
USA V. PANGANG GROUP COMPANY, LTD. 19
immunity primarily because of the corporations’ separate
juridical status.”).
Courts generally gave three justifications for excluding
foreign state-owned entities engaged in ordinary commercial
activities from the domain of foreign sovereign immunity.
First, a corporation is distinct from its stockholders, and
therefore an action against the former (the foreign state-
owned corporation) is not an action against the latter (the
foreign state). See United States v. Deutsches Kalisyndikat
Gesellschaft, 31 F.2d 199, 202 (S.D.N.Y. 1929); Hannes v.
Kingdom of Roumania Monopolies Inst., 20 N.Y.S.2d 825,
832–33 (N.Y. App. Div. 1940); Ulen & Co. v. Bank
Gospodarstwa Krajowego, 24 N.Y.S.2d 201, 206–07 (N.Y.
App. Div. 1940). Second, none of the reasons for granting
immunity to the sovereign apply with equal force to a mere
corporation. See Molina v. Comision Reguladora del
Mercado de Henequen, 103 A. 397, 399 (N.J. 1918). That
is, asserting jurisdiction over a foreign corporation engaged
in ordinary commercial activities, even if state-owned, does
not comparably implicate “the independence of states, the
obligation of a sovereign not to degrade the dignity of his
nation by placing himself or its sovereign rights within the
jurisdiction of another, the perfect equality and absolute
independence of sovereigns, the common interest impelling
them to mutual intercourse and an interchange of good
offices with each other.” Id.; see also Ulen, 24 N.Y.S.2d at
204–05. Third, granting immunity to foreign state-owned
corporations engaged in ordinary commercial activities
would put domestic businesses at a potentially significant
and unfair competitive disadvantage. See Molina, 103 A. at
399.
Cases from this era denied foreign sovereign immunity
to foreign state-owned commercial entities across a range of
20 USA V. PANGANG GROUP COMPANY, LTD.
jurisdictions and types of actions. See, e.g., Deutsches, 31
F.2d 199; Coale v. Societe Co-op. Suisse des Charbons,
Basle, 21 F.2d 180 (S.D.N.Y. 1921); Hannes, 20 N.Y.S.2d
825; Molina, 103 A. 397; Ulen, 24 N.Y.S.2d 201. For
example, in Deutsches, a government action to enjoin
violations of antitrust laws, the ambassador of France
asserted that the defendant corporation was entitled to
foreign sovereign immunity because it was “created and
controlled by the Republic of France for the purpose of
administering potash mines,” the proceeds from the potash
it sold were “applied to governmental purposes,” and the
French government considered it to be an instrumentality of
government. 31 F.2d at 200. The district court disagreed,
holding that “[n]either principle nor precedent requires that
[foreign sovereign] immunity . . . should be extended to a
foreign corporation merely because some of its stock is held
by a foreign state, or because it is carrying on a commercial
pursuit, which the foreign government regards [as]
governmental or public.” Id. at 203.
Coale concerned “an action for failure to take and pay
for coal sold . . . under a written contract.” 21 F.2d at 180.
The defendant was a corporation chartered by the Swiss
government to purchase and import coal. See id. at 180–81.
Swiss nationals could contribute capital to the corporation in
exchange for six percent interest. See id. at 181. “[T]he
further net earnings, if any, were to pass to the government,
in order to reduce the price of coal for home consumption.”
Id. The government also retained some control over the
corporation: the government appointed seven of the 17
directors, and the corporation’s governing charter and rules
were subject to the government’s approval. See id. The
contract at issue in the case “was signed by the Swiss
[Finance] [M]inister on behalf of the [corporation] and the
USA V. PANGANG GROUP COMPANY, LTD. 21
Swiss Federation.” Id.; see also Rex v. Cia. Pervana de
Vapores, S.A., 660 F.2d 61, 72 (3d Cir. 1981) (Sloviter, J.,
dissenting). Nonetheless, the district court held that “[i]f the
Swiss government chose to do its business by means of the
[corporation], the latter, as a corporate entity, was liable for
its corporate obligations.” Coale, 21 F.2d at 181.
In Hannes, the defendant was “an autonomous corporate
entity” “wholly owned, operated and controlled by the
Kingdom of Roumania.” 20 N.Y.S.2d at 828. It was
“formed pursuant to the Laws of Roumania for the purpose
of exploiting certain monopolies, and of issuing bonds and
obtaining monies from investors by the sale of such bonds.”
Id. Roumanian law “provided that the operations of the
defendant were to be deemed commercial, and [that the]
defendant was to enjoy all the privileges and powers of
commercial companies.” Id. at 830. Though “legally
independent,” the corporation benefited from several
government “concessions”: the government granted it “the
exclusive right to exploit specified commercial monopolies”
for a price, and endowed its bonds with “all the benefits of
public loans of the government . . . , including exemption
from taxation.” Id. The corporation was managed by a
council “consisting mainly of public officers of Roumania,
or their appointees.” Id. Despite the Kingdom of
Roumania’s assertion that the corporation was entitled to
foreign sovereign immunity as a state instrumentality, see id.
at 832, the New York appellate court remanded the case to
more “definitely establish[]” “all of the essential facts
surrounding [the] defendant’s powers, liabilities, and its
relation to the Roumanian government,” id. at 834. In doing
so, the court held that foreign sovereign immunity does not
automatically extend to “a corporation . . . owned by [a
foreign] government, especially when such corporation is
22 USA V. PANGANG GROUP COMPANY, LTD.
engaged in commercial activities.” Id. at 832. On the
contrary, government-owned “[f]oreign corporations as such
are not entitled to immunity, even though their functions
may include to some extent the performance of public
duties.” Id. at 833.
In Molina, the defendant was “a corporation created by
the state of Yucatan[,] [Mexico] to carry out, or assist in
carrying out certain policies of that government with
reference to the growth and sale of sisal hemp, the most
important product of Yucatan.” 103 A. at 398. It submitted
a motion to dissolve, on foreign sovereign immunity
grounds, an attachment on sisal hemp that it had purchased
from the national government of Mexico. See id. The
Supreme Court of New Jersey rejected as “startling” the
“suggestion . . . that [foreign sovereign] immunity extends
to a foreign corporation if it is a governmental agency of a
political subdivision of a foreign government, or if a foreign
government is indirectly interested in the corporation
because its work contributes to the prosperity of the foreign
country.” Id. at 399. The court therefore denied the
corporation’s motion. See id. at 401.
In Ulen, the defendant was a bank chartered by “decree
of the President” of the Republic of Poland. 24 N.Y.S.2d at
202. Its charter mandated that the majority of the bank’s
shares be owned by the state treasury and state enterprises,
with the remaining shares owned by municipalities and
municipal enterprises. See id. at 203. “The objects of the
Bank were stated, in [its charter], to be the granting of long-
term credits through the issuance of bonds; the support of
savings institutions; the reconstruction of devastated lands;
and the conduct of all banking activities with particular
consideration for the needs of the State, State enterprises and
municipalities.” Id. The Minister of Finance had ultimate
USA V. PANGANG GROUP COMPANY, LTD. 23
control of the bank, and the bank was exempted from certain
state taxes. See id. In rejecting the bank’s claim to sovereign
immunity, the New York appellate court held that “a
corporation organized by either a domestic or foreign
government for commercial objects in which the
government is interested, does not share the immunity of the
sovereign.” Id. at 206.
By contrast, In re Investigation of World Arrangements
with Relation to the Production, Transportation, Refining &
Distribution of Petroleum, 13 F.R.D. 280 (D.D.C. 1952)
(“World Arrangements”), offers one example of a state-
owned corporation, the Anglo-Iranian Oil Company, that did
enjoy foreign sovereign immunity under the traditional
common-law rule. The Anglo-Iranian Oil Company was
formed by the British government for the express purpose of
ensuring an adequate supply of oil to the British fleet. See
id. at 290. The district court held that the company was
entitled to immunity from a grand jury subpoena because the
company was performing “a fundamental government
function serving a public purpose”—namely, “insur[ing] the
maintenance and operation of” “one of the island-kingdom’s
main bulwarks of defense against aggression.” Id. In doing
so, the district court distinguished the company from foreign
state-owned corporations engaged in ordinary commercial
activities, which were not entitled to foreign sovereign
immunity: “There is a vast distinction between a seafaring
island-nation maintaining a constant supply of maritime fuel
and a government seeking additional revenue in the
American markets.” Id. at 291. Some courts have likewise
held that foreign state-owned railways enjoyed foreign
sovereign immunity, but only after concluding that they
performed fundamental government functions, not merely
commercial ones, or that the railways were an actual agency
24 USA V. PANGANG GROUP COMPANY, LTD.
of government rather than a separate corporation. See, e.g.,
Oliver Am. Trading Co. v. Government of the U.S. of Mexico,
5 F.2d 659, 661, 665–67 (2d Cir. 1924) (holding that a suit
that was “nominally against both the government of Mexico
and the National Railways in Mexico” was “in reality a suit
only against the Mexican government” and that, because the
operation of railways was in many countries, including
Mexico, “regarded . . . as the performance of a fundamental
governmental function,” foreign sovereign immunity
required dismissal); Bradford v. Director Gen. of R.Rs. of
Mexico, 278 S.W. 251, 251–52 (Tex. Civ. App. 1925)
(affirming dismissal of suit against the “Director General of
Railroads of Mexico” on the grounds that the Mexican
railway was “not a corporation” and that the suit was
“against the government of Mexico” itself); Mason v.
Intercolonial Ry. of Canada, 83 N.E. 876, 876–77 (Mass.
1908) (affirming dismissal of suit against the Intercolonial
Railway of Canada, concluding that it was “not a
corporation” and that the suit was “virtually against the
[sovereign] of a foreign country”). Without expressing any
view as to the correctness of those decisions on their specific
facts, we note that their analysis is consistent with the
general rule that a separate corporation that does not perform
fundamental governmental functions does not partake of
foreign sovereign immunity.
In sum, the traditional common-law formulation of
foreign sovereign immunity that emerges from these cases is
one in which that immunity had broad scope but limited
domain—absolute immunity, but only for a limited set of
eligible persons and entities. 7 Cf. Halkbank III, 120 F.4th at
7
Notably, this accorded with the traditional common-law formulation of
domestic sovereign immunity. See, e.g., Bank of the U.S. v. Planters’
USA V. PANGANG GROUP COMPANY, LTD. 25
52 (“Courts applying the common law have long
distinguished between the immunity afforded to a foreign
state and to the entities that it owns.”).
B
The traditional common-law formulation of foreign
sovereign immunity underwent significant development
starting in 1952. See Rubin v. Islamic Republic of Iran, 583
U.S. 202, 208 (2018). That year, the Department of State
issued the “Tate Letter,” in which it announced that it would
adopt a “restrictive theory” of foreign sovereign immunity.
See Letter from Jack B. Tate, Acting Legal Adviser, U.S.
Dept. of State, to Acting U.S. Attorney General Philip B.
Perlman (May 19, 1952), reprinted in 26 DEPT. STATE BULL.
984–85 (1952). Under the restrictive theory, “the immunity
of the sovereign is recognized with regard to sovereign or
public acts (jure imperii) of a state, but not with respect to
private acts (jure gestionis).” Id. at 984. Notably, this
restriction on foreign sovereign immunity was based solely
on the nature of the activity at issue, and it applied to all
entities within the domain of foreign sovereign immunity,
even the sovereign itself. See id. The restrictive theory
therefore narrowed the scope of foreign sovereign
Bank of Georgia, 22 U.S. 904, 907 (1824) (“[W]hen a government
becomes a partner in any trading company, it devests itself, so far as
concerns the transactions of that company, of its sovereign character, and
takes that of a private citizen.”); Briscoe v. Bank of Kentucky, 36 U.S.
257, 325–26 (1837) (“[A] state, when it becomes a stockholder in a bank,
imparts none of its attributes of sovereignty to the institution; and . . .
this is equally the case, whether it own a whole or a part of the stock of
the bank.”); Sloan Shipyards Corp. v. United States Shipping Bd.
Emergency Fleet Corp., 258 U.S. 549, 567–68 (1922) (“The plaintiffs
are not suing the United States but the Fleet Corporation, and if its act
was unlawful, even if they might have sued the United States, they are
not cut off from a remedy against the agent that did the wrongful act.”).
26 USA V. PANGANG GROUP COMPANY, LTD.
immunity—from absolute immunity, to immunity only
when the challenged conduct was a sovereign or public act
of the state—without necessarily altering the domain.
The influence of the Tate Letter is reflected in two
subsequent assessments of the state of the common law. One
was an analysis undertaken by the Department of Justice and
the Department of State in a joint submission to Congress
related to its consideration of an early draft of the FSIA. See
A Bill to Define the Circumstances in Which Foreign States
Are Immune from the Jurisdiction of the United States
Courts and in Which Execution May Not Be Levied on Their
Assets, and For Other Purposes: Hearing on H.R. 3493
Before the Subcomm. on Claims and Governmental Rels. of
the H. Comm. on the Judiciary, 93d Cong. 33–48 (1973). In
their analysis, the Departments first noted that, before the
Tate Letter was issued, the doctrine of foreign sovereign
immunity was broad in scope and limited in domain. See id.
at 39 (“When the principle of the absolute immunity of
foreign governments was still dominant, the idea of the
separability of certain governmental agencies or
instrumentalities was used to exempt certain governmental
activities from the rule of absolute immunity.”). After the
Tate Letter was issued, the Departments noted, courts began
to restrict the scope of foreign sovereign immunity, while
sometimes retaining the traditional limits on the domain of
foreign sovereign immunity as either an alternative or a
complement to the newer restrictions on scope. See id.
(“When the trend shifted toward restricted immunity, some
courts retained the old distinction as well, thus applying a
double standard, namely that there is no immunity if an
activity is commercial or if it is conducted by a separate
entity. In [other] instances, immunity was abolished only
USA V. PANGANG GROUP COMPANY, LTD. 27
when the transaction was commercial and the entity was a
separate one.”).
The Restatement (Second) of Foreign Relations Law
(1965) (“RESTATEMENT”) also reflected the influence of the
Tate Letter’s restrictive theory of foreign sovereign
immunity. According to its assessment of the state of the
common law at the time, both the domain and the scope of
foreign sovereign immunity were circumscribed. According
to § 66(g), a corporation fell within the domain of foreign
sovereign immunity only if it was “created under [a foreign
state’s] laws and exercis[ed] functions comparable to those
of an agency of the [foreign] state.” RESTATEMENT, supra,
§ 66(g); cf. Halkbank III, 120 F.4th at 54 (“[T]he few courts
that did extend immunity to state-owned corporations
emphasized those entities’ performance of governmental
functions.”). And, according to § 69, the scope of an eligible
entity’s immunity did not extend to “proceeding[s] arising
out of commercial activity outside [the foreign state’s]
territory.” RESTATEMENT, supra, § 69.
C
Enacted in 1976, the FSIA expanded on the Tate Letter’s
approach of limiting foreign sovereign immunity based
principally on scope. See Verlinden, 461 U.S. at 488 (“For
the most part, the [FSIA] codifies . . . the restrictive theory
of sovereign immunity.”). In particular, the FSIA
established, among several enumerated exceptions to foreign
sovereign immunity, that an entity’s immunity does not
extend to actions that are sufficiently connected to
commercial activity. See 28 U.S.C. § 1605(a)(2). But the
statute goes a step further than the Tate Letter by broadening
the domain of foreign sovereign immunity beyond its
common-law boundaries: it confers immunity on any foreign
28 USA V. PANGANG GROUP COMPANY, LTD.
corporation in which a foreign state directly has majority
ownership, even if the corporation is engaged in ordinary
commercial activities. See 28 U.S.C. §§ 1603, 1604. The
FSIA thus inverted the traditional common-law rule that
existed before the Tate Letter—from immunity with broad
scope and limited domain, to immunity with a broader
domain and a more limited scope.
We discern no support for transposing the FSIA’s
legislative expansion of the domain of foreign sovereign
immunity into the common law—especially as it pertains to
criminal immunity, which Halkbank II confirmed the FSIA
“does not cover.” Halkbank II, 598 U.S. at 272–73; see also
id. at 273–75. Nor does either side in this case advocate that
we do so. On the contrary, both sides agreed at oral
argument that § 66(g) of the Restatement best states the
common-law standard for assessing the domain of foreign
sovereign immunity in the criminal context. That position is
sensible. Because the FSIA’s enactment in 1976 effectively
froze the application, and thus the development, of the
common law with respect to state-owned entities until
Halkbank II clarified that the common law remains
applicable in criminal cases, the Restatement’s account of
the common law, to the extent it accurately summarizes the
then-existing body of caselaw, is instructive. See, e.g.,
Doğan v. Barak, 932 F.3d 888, 893–94 (9th Cir. 2019)
(citing the Restatement to ascertain the common law on the
sovereign immunity of individual foreign officials after the
Supreme Court held that the FSIA did not govern the
matter). We therefore turn to § 66(g) of the Restatement in
determining whether foreign state-owned entities fall within
the common-law domain of foreign sovereign immunity.
In doing so, we note that the § 66(g) test of whether an
entity “exercis[es] functions comparable to those of an
USA V. PANGANG GROUP COMPANY, LTD. 29
agency of the state” bears some resemblance to our test of
whether an entity constitutes an “organ of a foreign state”
under the FSIA, 28 U.S.C. § 1603(b)(2). See California
Dep’t of Water Res. v. Powerex Corp., 533 F.3d 1087, 1098
(9th Cir. 2008) (“An entity is an organ of a foreign state (or
political subdivision thereof) if it ‘engages in a public
activity on behalf of the foreign government.’” (quoting
Patrickson v. Dole Food Co., 251 F.3d 795, 807 (9th Cir.
2001))). The Government’s view is that the two tests share
the same core inquiry but are not coextensive. We need not
decide that point here. Nonetheless, as our application of the
§ 66(g) test will show, we find caselaw construing the
FSIA’s concept of an “organ of a foreign state” to be
instructive.
IV
Section 66(g) of the Restatement extends “[t]he
immunity of a foreign state” to “a corporation created under
its laws and exercising functions comparable to those of an
agency of the state.” RESTATEMENT, supra, § 66(g). “The
term ‘agency’ as used in this Section means a body having
the nature of a government department or ministry.”
RESTATEMENT, supra, § 66 cmt. a.
We hold that the Pangang Companies have not made a
prima facie showing that they exercise functions comparable
to those of an agency of the PRC. They therefore are not the
kinds of entities eligible for foreign sovereign immunity
from criminal prosecution.
Neither the allegations in the indictment nor anything
else in the record establishes a prima facie claim that the
Pangang Companies exercise functions comparable to those
of an agency of the PRC. The documents in the record
primarily address the Pangang Companies’ ownership
30 USA V. PANGANG GROUP COMPANY, LTD.
structure and the specific actions they allegedly took in
violation of the EEA. They paint a portrait of an ordinary
commercial enterprise engaged in the production of steel and
non-ferrous metals. But that sort of conventional corporate
entity is not one that “exercis[es] functions comparable to
those of an agency of the state.” RESTATEMENT, supra,
§ 66(g).
The Pangang Companies’ arguments to the contrary are
unpersuasive. First, the Pangang Companies point to the fact
that they were controlled by the PRC through the SASAC.
But immunity under § 66(g) turns on the functions the
corporation exercises, not on the corporation’s ownership or
control. The mere fact that a foreign state owns and controls
a corporation is not sufficient to bring the corporation within
the ambit of § 66(g). See, e.g., Hannes, 20 N.Y.S.2d at 828
(holding that the defendant corporation had not established
foreign sovereign immunity notwithstanding that it
“appear[ed] to be wholly owned, operated and controlled by
the Kingdom of Roumania”). Nor does the fact that the PRC
directs state-owned entities with an eye toward coordinating
the national economy imply that any individual state-owned
entity exercises functions comparable to those of a state
agency. See, e.g., Ulen, 24 N.Y.S.2d at 203 (denying
immunity to a bank created by foreign sovereign to provide
structural support to the national economy). The Pangang
Companies’ allegations of SASAC control therefore do not
establish a prima facie case.
The Pangang Companies also argue that their theft of
DuPont’s TiO2 trade secrets involved sovereign
techniques—namely, espionage—and accomplished the
PRC’s public objective of developing chloride-route TiO2
production technology. But the commercial espionage
alleged here is not a function comparable to that of an agency
USA V. PANGANG GROUP COMPANY, LTD. 31
of the state and therefore does not qualify the Pangang
Companies for immunity under § 66(g). Not all acts of
espionage are necessarily sovereign in nature. In Broidy
Capital Management, LLC v. State of Qatar, 982 F.3d 582
(9th Cir. 2020), we held that a foreign state’s clandestine
cyberattacks to obtain and disseminate compromising
private information about critics of the state were an exercise
of “powers that . . . are ‘peculiar to sovereigns.’” Id. at 594
(quoting Saudi Arabia v. Nelson, 507 U.S. 349, 360 (1993)).
We found that the absence of any allegation that the foreign
state used the stolen information commercially supported
our conclusion in that case. See id. at 595; see also id.
(recognizing that “what a foreign sovereign does with
covertly obtained intelligence” informs whether the
espionage conducted was commercial or sovereign in
nature). By contrast, we recognized, “stealing the trade
secrets of a ‘commercial rival’ and deploying them against
that rival,” though also an act of espionage involving the
theft of private information, would be an “objective[ly]
differen[t]” kind of action that is not peculiar to sovereigns.
Id.; see also Cicippio v. Islamic Republic of Iran, 30 F.3d
164, 168 (D.C. Cir. 1994) (distinguishing a kidnapping of
another country’s national for leverage in international
negotiations from a kidnapping of a commercial rival). The
commercial espionage alleged here more closely resembles
this latter kind of theft: the indictment and other documents
filed in this case, on their face, indicate that the stolen
information was sought and subsequently used for
commercial gain.
At most, the Pangang Companies can point to the fact
that the commercial gains that flowed from the stolen trade
secrets helped to achieve the PRC’s publicly identified
priority of developing chloride-route TiO2 production
32 USA V. PANGANG GROUP COMPANY, LTD.
technology. But this priority was alleged to be merely
“scientific and economic” in character. In any event, a
generalized public benefit from a commercial enterprise’s
economic exploitation of stolen trade secrets is not enough
to transform that industrial espionage into the exercise of a
function comparable to that of a state agency. See
Deutsches, 31 F.2d at 203 (rejecting the theory that
immunity extends to a corporation merely “because it is
carrying on a commercial pursuit, which the foreign
government regards governmental or public”); Halkbank III,
120 F.4th at 57–58 (“[I]t is well established that a motivation
to advance the national economy is insufficient to confer
immunity to otherwise commercial conduct.”); cf. World
Arrangements, 13 F.R.D. at 290 (recognizing functions
essential to national defense to be comparable to those of a
state agency).
In arguing for a contrary conclusion, the Pangang
Companies rely heavily on World Arrangements and
Powerex—but those cases are distinguishable because the
defendants there exercised functions comparable to those of
a state agency. As discussed previously, World
Arrangements granted immunity because the defendant’s
“supplying of oil to insure the maintenance and operation of
a naval force . . . [was] certainly a fundamental government
function serving a public purpose.” 13 F.R.D. at 290
(emphasis added). Likewise, in Powerex, we held that a
Canadian corporation that marketed and distributed electric
power for an entire province was “engage[d] in a public
activity on behalf of the foreign government,” 533 F.3d at
1098 (emphasis added) (quoting Patrickson, 251 F.3d at
807), and hence qualified as an organ of a foreign state
within the meaning of the FSIA, see id. at 1098–102. We
reached this conclusion because the corporation performed
USA V. PANGANG GROUP COMPANY, LTD. 33
sovereign functions “in furtherance of policies adopted by
the Province [of British Columbia],” including “suppl[ying]
power on favorable terms to expanding businesses in British
Columbia,” “negotiat[ing] on behalf of the Province with
‘industrial undertakings’ that have considered establishing
facilities in the Province,” “play[ing] a role in treaty
formation and implementation,” and “serv[ing] as the
vehicle for the Province’s . . . attempt to create an auction
market for electricity trading.” Id. at 1100. As discussed
previously, the documents filed in this case do not remotely
suggest that the Pangang Companies played this kind of
governmental role.
A case more analogous to the one at hand, and which
supports our conclusion, is our decision in Patrickson.
There, two Israeli companies argued that they were organs
of a foreign state under the FSIA because they were “created
by Israel for the purpose of exploiting the Dead Sea
resources owned by the government” and “were classified as
‘government companies’ under Israeli law, which gave the
government certain privileges reflecting its ownership
stake.” 251 F.3d at 808. The appointment of directors and
officers, changes to capital structure, and the use of
corporate profits were subject to the government’s approval,
and the companies “were obliged to present an annual
budget and financial statement to various government
ministries.” Id.
Nonetheless, we held that the Israeli companies were not
organs of a foreign state. See Patrickson, 251 F.3d at 808.
We observed that the Israeli government’s control over the
companies “[was] not considerably different from the
control a majority shareholder would enjoy under American
corporate law.” Id. And, we noted, the Israeli companies
were distinguishable from companies that prior caselaw had
34 USA V. PANGANG GROUP COMPANY, LTD.
deemed to be organs. See id. These other companies had
additional factors weighing in favor of organ status beyond
mere shareholder control. One was “controlled by
government appointees; employed only public servants; and
had the exclusive responsibility for refining and distributing
[foreign] government property.” Id. (citing Corporacion
Mexicana de Servicios Maritimos, S.A. de C.V. v. M/T
Respect, 89 F.3d 650, 654–55 (9th Cir. 1996)). Another
“exercised regulatory authority delegated by the
government; its decisions could be appealed to a government
agency; and its members enjoyed immunity from suit for
their official duties.” Id. (citing Gates v. Victor Fine Foods,
54 F.3d 1457, 1461 (9th Cir. 1995)). Because the Israeli
companies in Patrickson lacked many of these factors, we
viewed them “as independent commercial enterprises,
heavily regulated, but acting to maximize profits rather than
pursue public objectives.” Id.
Like the Israeli companies in Patrickson, the Pangang
Companies lack any such distinguishing factors. Nothing in
the record indicates, for example, that the Pangang
Companies were created by the PRC with the purpose of
exploiting or administering exclusive state property, that
they employ only public servants, or that they exercise any
regulatory or public authority over others. They may operate
in a heavily regulated sector of the Chinese economy at the
direction of the PRC, but that alone is not enough to establish
immunity under § 66(g).
Because the record does not suggest that the Pangang
Companies are anything more than conventional corporate
entities engaged in commercial activities, the Pangang
Companies fail to establish a prima facie case that they are
entities “exercising functions comparable to those of an
agency of the state.” RESTATEMENT, supra, § 66(g).
USA V. PANGANG GROUP COMPANY, LTD. 35
Therefore, under the Restatement’s test, which aptly
summarizes the relevant standard, they are not entitled to
foreign sovereign immunity under federal common law.
V
Finally, to the extent that we had any residual doubt
about the correctness of our conclusion, principles of
deference to the political branches on matters touching on
foreign relations firmly counsel against recognizing foreign
sovereign immunity here.
“For much of our history, claims of foreign sovereign
immunity were handled on a piecework basis . . . .” Opati v.
Republic of Sudan, 590 U.S. 418, 420–21 (2020).
“Typically, after a [private] plaintiff sought to sue a foreign
sovereign in an American court, the Executive Branch,
acting through the State Department, filed a ‘suggestion of
immunity’—case-specific guidance about the foreign
sovereign’s entitlement to immunity.” Id. at 421 (emphasis
added); see also Samantar v. Yousuf, 560 U.S. 305, 311
(2010); RESTATEMENT, supra, § 71 cmt. a. “Because foreign
sovereign immunity is a matter of ‘grace and comity,’ and
so often implicates judgments the Constitution reserves to
the political branches, courts ‘consistently . . . deferred’ to
these suggestions.” Opati, 590 U.S. at 421 (citations
omitted); see, e.g., Schooner Exchange, 11 U.S. at 147; Ex
parte Peru, 318 U.S. 578, 586–90 (1943); Hoffman, 324 U.S.
at 30–37; Bank Markazi v. Peterson, 578 U.S. 212, 235
(2016) (“[C]ourts accepted [the Executive Branch’s]
determinations as binding.”).
This case, of course, does not involve a private plaintiff
at all. It is a criminal prosecution brought by the Executive
Branch in the name of the United States. Without inquiring
into what internal processes the Executive Branch followed
36 USA V. PANGANG GROUP COMPANY, LTD.
before filing this case, we cannot help but conclude that a
prosecution pursued for 13 years by the Executive Branch
against the Pangang Companies—in the face of their
persistent claims of foreign sovereign immunity—reflects
the Executive Branch’s considered judgment that the
companies do not qualify for immunity. See, e.g., Halkbank
III, 120 F.4th at 49 (“[T]he decision to bring federal criminal
charges against Halkbank reflects the Executive Branch’s
determination that Halkbank is not entitled to sovereign
immunity . . . .”); United States v. Noriega, 117 F.3d 1206,
1212 (11th Cir. 1997) (“[B]y pursuing Noriega’s capture and
this prosecution, the Executive Branch has manifested its
clear sentiment that Noriega should be denied head-of-state
immunity.”); cf. Pasquantino v. United States, 544 U.S. 349,
369 (2005) (“[W]e may assume that by electing to bring this
prosecution, the Executive has . . . concluded that it poses
little danger of causing international friction.”); Mujica v.
AirScan Inc., 771 F.3d 580, 609–11 (9th Cir. 2014)
(deferring to the Executive Branch’s preference for
dismissal in a matter involving foreign policy); Alfred
Dunhill of London, Inc. v. Republic of Cuba, 425 U.S. 682,
699 (1976) (regarding as “severely diminished” the authority
of a prior case in which the Supreme Court had granted
immunity despite the absence of any suggestion of immunity
by the Executive Branch).
The deference we accord under the common law to the
Executive Branch’s sustained prosecution of this case only
reinforces our conclusion that, under federal common law,
USA V. PANGANG GROUP COMPANY, LTD. 37
the Pangang Companies are not entitled to immunity.
Accord Halkbank III, 120 F.4th at 48–49. 8
* * *
For the foregoing reasons, we affirm the district court’s
order denying the Defendants’ motion to dismiss the
indictment.
AFFIRMED.
8
Like the Second Circuit in Halkbank III, “we leave for another day
whether deference to the Executive in this context should be cabined if,
unlike here, the Executive’s denial of immunity to a foreign sovereign
derogated from the common law.” Halkbank III, 120 F.4th at 59.
Plain English Summary
FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT UNITED STATES OF AMERICA, No.
Key Points
01FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT UNITED STATES OF AMERICA, No.
024:11-cr-00573- JSW-7 PANGANG GROUP COMPANY, 4:11-cr-00573- LTD.; PANGANG GROUP STEEL JSW-8 VANADIUM & TITANIUM 4:11-cr-00573- COMPANY, LTD.; PANGANG JSW-9 GROUP TITANIUM INDUSTRY 4:11-cr-00573- COMPANY, LTD.; PANGANG JSW-10 GROUP INTERNATIO
03White, District Judge, Presiding Argued and Submitted January 26, 2024 Pasadena, California Filed April 28, 2025 2 USA V.
04Opinion by Judge Collins SUMMARY * Criminal Law / Foreign Sovereign Immunity The panel affirmed the district court’s denial of a motion to dismiss an indictment charging four affiliated companies (“the Pangang Companies”) with economic espi
Frequently Asked Questions
FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT UNITED STATES OF AMERICA, No.
FlawCheck shows no negative treatment for United States v. Pangang Group Company, Ltd. in the current circuit citation data.
This case was decided on April 28, 2025.
Use the citation No. 10386175 and verify it against the official reporter before filing.